Magnetic resonance imaging (MRI) intensities are acquired in arbitrary units, making scans non-comparable across sites and between subjects. Intensity normalization is a first step for the improvement of comparability of the images across subjects. However, we show that unwanted inter-scan variability associated with imaging site, scanner effect and other technical artifacts is still present after standard intensity normalization in large multi-site neuroimaging studies. We propose RAVEL (Removal of Artificial Voxel Effect by Linear regression), a tool to remove residual technical variability after intensity normalization. As proposed by SVA and RUV [Leek and Storey, 2007 , Gagnon-Bartsch and Speed, 2012 , two batch effect correction tools largely used in genomics, we decompose the voxel intensities of images registered to a template into a biological component and an unwanted variation component. The unwanted variation component is estimated from a control region obtained from the cerebrospinal fluid (CSF), where intensities are known to be unassociated with disease status and other clinical covariates. We perform a singular value decomposition (SVD) of the control voxels to estimate factors of unwanted variation. We then estimate the unwanted factors using linear regression for every voxel of the brain and take the residuals as the RAVEL-corrected intensities. We assess the performance of RAVEL using T1-weighted (T1-w) images from more than 900 subjects with Alzheimer's disease (AD) and mild cognitive impairment (MCI), as well as healthy controls from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. We compare RAVEL to intensity-normalization-only methods, histogram matching, and White Stripe. We show that RAVEL performs best at improving the replicability of the brain regions that are empirically found to be most associated with AD, and that these regions are significantly more present in structures impacted by AD (hippocampus, amygdala, parahippocampal gyrus, enthorinal area and fornix stria terminals). In addition, we show that the RAVEL-corrected intensities have the best performance in distinguishing between MCI subjects and healthy subjects by using the mean hippocampal intensity (AUC=67%), a marked improvement compared to results from intensity normalization alone (AUC=63% and 59% for histogram matching and White Stripe, respectively). RAVEL is generalizable to many imaging modalities, and shows promise for longitudinal studies. Additionally, because the choice of the control region is left to the user, RAVEL can be applied in studies of many brain disorders.
Introduction
In recent years, there has been an increase in the number of multi-site neuroimaging studies, including the Human Connectome Project (HCP), the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Aging (AIBL). In structural magnetic resonance imaging (MRI) studies, larger samples of subjects yield more power to detect structural variations in different subgroups, for example changes in the hippocampal volume associated with Alzheimer's disease (AD) and mild cognitive impairment (MCI). However, because MRI intensities are acquired in arbitrary units, it has often been found that the differences in MRI intensities between scanning parameters and studies are larger than the biological differences observed in these images. For instance, Shinohara et al. [2014] shows that in the ADNI and AIBL studies, which have highly standardized protocols, striking differences in the raw intensities are observed between imaging sites.
As MRI are acquired in arbitrary units, scans are non-comparable across sites and between subjects. Therefore, intensity normalization is paramount before performing any between-subject comparisons or populationlevel modeling. The challenge of intensity normalization has been largely addressed in the literature [Nyúl and Udupa, 1999 , Nyúl et al., 2000 , Weisenfeld and Warfield, 2004 , Jager et al., 2006 , Madabhushi et al., 2006 , Leung et al., 2010 , Shinohara et al., 2011 , 2014 , with several methods reviewed in [Shah et al., 2011] . Recently, a novel intensity normalization method, called White Stripe [Shinohara et al., 2014] , was developed to bring raw image intensities to a biologically interpretable intensity scale. The method applies a z-score transformation to the whole brain using parameters estimated from a latent subdistribution of normal-appearing white matter (NAWM). The use of NAWM for normalization makes the method suitable for many studies of brain abnormalities, as in the case of multiple sclerosis (MS) lesions. While the method has been shown to make the white matter (WM) comparable across subjects, it was noted that residual across-subject variability was still present in the grey matter (GM).
In this work, we investigate between-scan technical variability that is left uncorrected by intensity normalization. We show that while common intensity normalization methods successfully correct for global intensity shifts associated with scanner site, substantial between-scan technical variation remains. This technical variation can be due to scanning parameters, scanner manufacturers, scanner field strength, and other factors. We refer to any post-normalization inter-scan variation that is not biological in nature as a "scan effect".
To correct for scan effects, we propose Removal of Artificial Voxel Effect by Linear regression (RAVEL). RAVEL is a tool for removing unwanted variation present after intensity normalization. RAVEL is inspired by the batch effect correction tools SVA Storey, 2007, 2008] and RUV [Gagnon-Bartsch and Speed, 2012] used broadly in genomics. In the analysis of gene expression and other genomic data, residual noise after intensity normalization is referred to as batch effects, because experiments are often performed in batches run on different dates. If not accounted for, batch effects have been shown to lead to spurious associations [Leek et al., 2010] . To make a parallel with brain imaging studies, the problem of batch effect correction is comparable to the problem of scan effect correction, where a single scan plays the role of a batch.
We use the linear model introduced in [Leek and Storey, 2007] to decompose the variation of the normalized intensities into a biological component of interest (variation associated with clinical covariates) and an unknown, unwanted variation component to be estimated from the data. The unwanted variation component encapsulates both technical variation and biological variation that is not of interest in the study. We register the different scans to a common template to allow the use of voxel-wise linear models, and estimate the unwanted variation component from regions of the brain that are not expected to be associated with the clinical covariates of interest. This follows the methodology of the RUV batch effect correction tool [Gagnon-Bartsch and Speed, 2012] which was later discussed in [Leek, 2014] for RNA sequencing. Unlike intensity-normalization methods, RAVEL utilizes all images in the study to leverage information about unwanted variability. Here, we use voxels that are consistently labelled as cerebrospinal fluid (CSF) across subjects as a control region; these voxels are not expected to be associated with disease [Luoma et al., 1993] .
We evaluate the performance of RAVEL using a large subset of the ADNI database consisting of more than 900 subjects. We demonstrate our method by using the T1-weighted (T1-w) images from subjects with AD and MCI, as well as healthy controls. We follow the work of Fortin et al. [2014] to benchmark RAVEL against two intensity normalization procedures without any scan effect correction: the popular histogram matching algorithm and White Stripe. We focus on showing that RAVEL improves the replicability of the biological findings. Critically, we show that a reduction of technical variation does not result in removing biological variability. Namely, making intensity densities more similar does not necessarily improve sensitivity to biological changes; on the contrary, overmatching of distributions can result in the removal of biologically relevant signal. To show improvement in terms of biological findings, we first demonstrate that the top voxels associated with AD in the RAVEL-corrected dataset are more replicable across independent subsets of subjects. We measure the replicability of the results by randomly splitting the ADNI dataset into discovery and validation cohorts multiple times. Then, we show that the top voxels associated with AD after RAVEL correction are more enriched for brain regions known to undergo structural changes in AD. Finally, we show that the average hippocampal intensity after RAVEL correction performs better than intensity-normalized-only images in discriminating between AD patients and healthy controls, and between MCI patients and healthy controls. This shows that RAVEL-corrected T1-w intensities are more biologically meaningful than intensity-normalized-only images for group comparisons, and therefore potentially promising for the development of biomarkers.
Although we apply RAVEL in the context of T1-w MRI of the brain, our method is generalizable to many imaging modalities. In addition, the flexibility in the choice of the control voxels makes RAVEL applicable to any disease or pathology.
Materials and methods

Study population
Our dataset consists of a subset of 917 subjects downloaded from the ADNI database (adni.loni.usc. edu). For each subject, we selected a study visit at random. We obtained 506, 184 and 227 subjects from the ADNI, ADNI-2 and ADNI-GO phases, respectively. We present summary statistics of the study population in Table 1 . The selected scans were acquired at 83 different imaging sites, with a median number of 10 patients per site. The scans were also well-balanced for disease status across sites. 
Imaging sequences and preprocessing
We considered T1-w imaging acquired on 1.5 and 3 T scanners according to the ADNI standardized protocol . All analysis was performed in R [R Core Team, 2014] , using the packages oro.nifti [Whitcher et al., 2011] , fslr , ANTsR [Avants et al., 2015] and WhiteStripe [Shinohara and Muschelli, 2015] .
We applied the N4 inhomogeneity correction algorithm [Tustison et al., 2010 ] to each image. We nonlinearly registered all T1-w images to a high-resolution T1-w image atlas [Oishi et al., 2010] , using the symmetric diffeomorphic image registration algorithm [Avants et al., 2008] implemented in the ANTs suite. We use non-linear registration in order to define a brain control region aligned across subjects and to find spatially coherent nuisance patterns for removal. To remove extra-cerebral tissue from each scan, we first created a brain mask on the template using the skull-stripping algorithm FSL BET [Smith, 2002] using the fslr package and subsequently applied this resulting brain mask to all N4-corrected and registered images. The preprocessing pipeline is summarized at the top of Figure 1 .
In addition to the template brain segmentation, we performed a 3-class tissue segmentation by running the FSL FAST segmentation algorithm [Zhang et al., 2001 ] on the N4-corrected, registered and skull-stripped images for each subject separately.
RAVEL methodology
The RAVEL correction procedure adapts the linear model introduced in SVA Storey, 2007, 2008 ] to intensity-normalized MRI images. The goal is to remove remaining unwanted variation in the normalized intensities by modeling the residual unwanted variation across subjects. For the optimal performance of RAVEL, we use intensities normalized with White Stripe (see Supplementary Figure S1a) . We model the m × n matrix V WS of registered and White Stripe-normalized voxel intensities, for m voxels and n subjects, as a decomposition of a biological component of interest and an unwanted component as follows:
where α1 T represents the average scan in the sample, βX T accounts for the known clinical covariates of interest, and γZ T accounts for unknown, unwanted factors. We refer to V WS as the m × n matrix of intensities, α as the m × 1 vector of baseline intensities, X as the n × p matrix of clinical covariates, β as the m × p coefficient matrix associated with X, Z as the n × b matrix of unwanted factors, γ as the m × b coefficient matrix associated with Z, and R as the m × n matrix of residuals. In this model, α, β, γ and Z are unknown parameters that need to be estimated from the data. In the case the unwanted factors Z are known, the problem is reduced to simple linear regression models fit at each voxel separately.
As in RUV [Gagnon-Bartsch and Speed, 2012] , we use a subset of the voxels not associated with disease to estimate the unwanted factors Z T . We refer to such voxels as "control voxels". An association between CSF intensities and disease status is highly unlikely [Luoma et al., 1993] , and therefore CSF voxels are good candidates for inferring the unwanted component in the data. We perform a subject-specific tissue segmentation of the T1-w image and choose control voxels as voxels classified as CSF for all subjects in the study. We denote by V WS c the subset of the matrix of White Stripe-normalized intensities V WS confined to the control voxels. For the control voxels, Equation 1 simplifies to
because of the absence of association between the control voxels and X. To estimate the unwanted factors Z T , we perform a singular value decomposition (SVD) of V WS C as follows
and defineẐ T to be the first b right-singular vectors {w 1 , w 2 , . . . , w b } of W. The choice of b is discussed in the next section. Note that for b = 1, the estimatorẐ T will closely estimate the average CSF intensity for each subject. We obtain the estimatesγ i in Equation 1 by performing a linear regression at each voxel separately, using our estimate of Z T in the equation. We define the RAVEL-corrected voxel i for subject j as
where v WS ij is the White Stripe-normalized intensity for the i-th voxel and for the j-th subject. In summary, RAVEL aims to identify patterns of variation in the control voxels across subjects, and then assess the degree to which this variation explains the brain-wide intensity distributions. In practice, this works well if the space spanned by the unwanted factors estimated from the control voxels also spans the unwanted variation space for all voxels. A schematic of the RAVEL method is presented in Figure 1 .
Estimation of the number of unwanted factors
We select the optimal number of unwanted factors b to include in Equation 1 by maximizing the discoveryvalidation replication rate described in section 2.7. Normalized intensities for which the top voxels associated with disease have better replication between independent experiments are more robust to technical artifacts, like site effect and differences in protocol.
Other approaches have been proposed to select b. Among others, Gagnon-Bartsch and Speed [2012] use voxels that are known to be associated with a clinical outcome to optimize b. They perform a sensitivity analysis for the parameter b, and b is chosen to optimize the number of positive control voxels that fall into the top voxels associated with the outcome. The downside of using this approach is that positive controls must be identified in advance, which is not possible for discovery studies.
Alternatively, the estimation of b could be done in an unsupervised manner by thresholding the percentage of variance explained by the first b singular vectors. This approach, which is agnostic of the outcome, can potentially provide additional safeguards against over-fitting, but could also decrease the performance of RAVEL by adding noise.
Comparison to intensity normalization methods
We compare RAVEL to two intensity normalization procedures without scan effect correction: White Stripe, as implemented in Shinohara and Muschelli [2015] , and the popular histogram matching method proposed by [Nyúl and Udupa, 1999] and further refined in [Shah et al., 2011] . The histogram matching method matches the histograms of each subject to a reference population histogram using a piecewise linear transformation. We implemented the algorithm in R and we made the code available at https: //github.com/Jfortin1/RAVEL/blob/master/R/hm.R. For better performance, we removed the background voxels before running the histogram matching algorithm. We used healthy subjects to form a reference population histogram distribution, as described in Shinohara et al. [2014] . 
Identification of voxels associated with clinical covariates
Here we describe how we perform the voxel-wise analysis of the intensity distributions. For a clinical covariate x, (e.g. disease status, age, gender), we perform a simple linear regression at each voxel of the T1-w voxel intensity v on the clinical covariate x, and consider the usual t-statistic as a measure of the strength of association. We obtain a t-statistic for each of the m voxels, that is a list {t 1 , t 2 , . . . , t m }, and we rank the t-statistics in a decreasing order to get a list of rank indices {r 1 , r 2 , . . . , r m } where r j is such that t r j = t (m−j) , the latter being (m − j)-th order statistic. For a chosen threshold q, we call the top q ranked voxels the "top voxels associated with x".
Evaluating the replicability of the top voxels associated with AD
To evaluate the replicability of the biological findings, that is the chance that an independent experiment will produce consistent results [Leek and Peng, 2015] , we devised a discovery-validation cohorts scheme inspired by [Fortin et al., 2014] . The goal of the scheme is to measure replicability of the top voxels associated with the outcome of interest. If not specified otherwise, we use the disease status (AD or healthy) as the outcome of interest; we include the patients with MCI for the biomarker study described in Section 3.4 only. The discovery-validation scheme is as follows: we randomly split the full dataset into two equally sized subsets that we call discovery and validation cohorts, assigning AD and healthy patients equally between the two cohorts.
For each of the two cohorts separately, we perform a differential analysis as described in Section 2.6 to obtain two lists of ranked voxels using the differential t-statistics: To quantify uncertainty of the overlap measure O(k), we repeat the random discovery-validation cohort splitting one hundred times, and present the mean curve along with a 95% confidence band.
Pseudo-ROC curves and enrichment curves
In this section, we review the methodology behind pseudo-ROC curves [Bourgon, 2006] and enrichment curves. We use these curves to evaluate the performance of the different normalization and scan effect removal methods by using prior information about structural changes associated with AD. In several neuroimaging studies, prior information about a specific disease allows us to expect a set of voxels to be associated with disease. For instance, a large proportion of the hippocampus and parahippocampal voxels are known to be associated with AD and MCI. In the absence of a gold standard, these voxels can play the role of a proxy for a gold standard. We refer to these voxels as a silver standard, that is a gold standard with some contamination.
In the context of genomics, silver standards have been previously used to compare the performance of different classification methods [Bourgon, 2006] and normalization methods [Schmid et al., 2010 , Fortin et al., 2014 . Bourgon [2006] show that receiver operating characteristic (ROC) curves based on a silver standard, called "pseudo-ROC curves", preserve the relative ranking of different classification methods with respect to ROC curves based on a gold standard. A sufficient condition for the validity of the pseudo-ROC curves ranking is that the contamination of the silver standard, with respect to the gold standard, occurs independently of the misclassification errors of the different methods compared. In the Results section, we use the t-statistics measuring the association of the voxel intensities with AD to classify voxels as either associated with AD or not. To estimate the sensitivity and specificity of each normalization method, we use voxels from 5 regions known to be associated with AD from an extensive search of the literature (see Table 2 ) as a silver standard.
Brain region References
Hippocampus Fox et al. [1996] , Mori et al. [1997] , Jack et al. [1999] Visser et al. A second approach for the benchmarking of different normalization/scan effect correction methods is to count the number of candidate voxels that fall into the list of the top k voxels associated with disease. We refer to the curve that depicts the counts for different values of k as the "enrichment curve".
Results
We compared RAVEL to three normalization strategies: raw image intensities (no normalization), White Stripe [Shinohara et al., 2014] , and histogram matching [Shah et al., 2011] . We recall that RAVEL correction was performed on the White Stripe-normalized intensities for better performance. (see Supplementary  Figure S1a ).
RAVEL reduces inter-subject variability
We used a subset of the CSF intensities as control voxels to estimate factors of unwanted variation in the RAVEL model. We obtained 9869 CSF control voxels; we recall that a voxel is qualified as a CSF control if it is classified as CSF for all subjects. As expected, the CSF control voxels were located primarily in the center of the ventricles (Figure 2a ). Maximizing the discovery-validation replication rate explained in the Methods section, we only kept the first singular vector as the unwanted factor term Z in Equation 1, corresponding to b = 1 (see Supplementary Figure S1b) . Unsurprisingly, the singular vector is highly correlated with the mean CSF intensity for each subject (correlation of 95.7%). In Figure 2b , we depict the coefficientγ at each voxel. We notice that the distribution ofγ varies across brain tissues, for instance darker red in WM and yellow in CSF. This shows that the method allows an unsupervised tissue-specific normalization. This prevents over-normalization in situations where the technical variation of the CSF intensities is not representative of the variation of other tissues.
In Figure 3 , we show the histograms of intensities before and after RAVEL correction. The first row shows the unnormalized image histograms and the second row shows the histograms for the images normalized with White Stripe. The last row depicts the histograms for the White Stripe-normalized images with RAVEL correction. In accordance with the findings of Shinohara et al. [2014] , the White Stripe-normalized images show good comparability of the WM across subjects. This can be seen by the similar WM densities centered around zero (Figure 3 second row, third column). For GM, the White Stripe densities are less clustered and show more variability, which is even more exaggerated for the CSF intensities. This shows that scaling and centering using a NAWM stripe is not enough to make GM and CSF intensities comparable across subjects. This can be explained by differential WM to GM and WM to CSF contrast ratios across images and protocols. In the third row, one can see that RAVEL substantially corrects for the extra variability in CSF and GM intensities that is not accounted for by intensity normalization. RAVEL also preserves the comparability of the WM intensities. The histograms for each tissue class cluster together well and show similar characteristics (mean, scale and range).
The main source of variation in the unnormalized images is from scanning site; on average, 67.8% of the variation in the intensities is explained by scanning site (R 2 averaged across voxels). Interestingly, we observed much less variation explained by scanning site for both intensity-normalized datasets (18% for both White Stripe and histogram matching) and for RAVEL (18%). We randomly permuted the scanning site variable 100 times and obtained a null distribution of the average R 2 with range of [16.1%, 16.5%]. This implies that after intensity normalization alone, the variability between different sites is close to the within-site variability. However, as shown in Figure 3 , RAVEL removes additional technical variability in comparison to intensity normalization alone.
RAVEL improves replicability of large MRI studies
We and others have shown in the study of large epigenetic data that the ability to reduce technical variation does not necessarily lead to a better detection of features associated with the outcome of interest [Fortin et al., 2014 , Dedeurwaerder et al., 2014 . A good normalization method should both reduce technical variability and enhance the replicability and robustness of biological findings. Here, we evaluate the performance of RAVEL in terms of estimating brain regions associated with AD.
We randomly split the ADNI dataset into discovery and validation cohorts one hundred times, and we present in Figure 4b the mean CAT curves with 95% confidence bands. As expected, the unnormalized data, that is the raw images intensities, show very poor replication of the results (maximum of 0.17), while RAVEL improves replication of the findings substantially (up to 0.65 overlap in the top findings) upon intensity normalization methods alone.
The replicated voxels fall into regions that are known to be associated with AD. In Figure 4a , we show voxels associated with AD that were replicated among the top 50,000 voxels for all random splittings. No normalization led to zero voxels replicated across splittings. This is not surprising since raw image intensities are expressed in arbitrary units. White Stripe replicated 1541 voxels, while histogram matching and RAVEL replicated 3758 and 4897 voxels respectively (Figure 4c ). In addition, RAVEL is the most powerful method for finding replicated voxels in the hippocampus and amygdala, two structures known to be associated with AD. The number of replicated voxels for the hippocampus are the following: 0 for no normalization, 396 for White Stripe, 1693 for histogram matching and 2405 for RAVEL. For the amygdala, we obtained the following counts: 0 for no normalization, 323 for White Stripe, 368 for histogram matching and 518 for RAVEL. The validity of those regions is discussed in the next section.
In summary, White Stripe and histogram matching, by correcting for inter-subject variability in the white matter, substantially increased the number of replicated voxels associated with AD in comparison to no normalization. RAVEL led to a 3-fold increase in the number of replicated voxels with respect to White Stripe. This was achieved by additionally modeling brain-wide unwanted variability using a CSF control region. This is consistent with the idea that while CSF is not interesting on its own with respect to disease, it can be used powerfully to distinguish signal from noise in the entire brain.
RAVEL uncovers known regions associated with AD
The discovery-validation scheme discussed above allowed us to evaluate the replicability of the top voxels associated with AD. In the current section, we aim to evaluate the validity of the results by comparing the top voxels to brain regions known to undergo a structural change in the progression of AD. Those structural changes include, among others, GM and WM atrophy, neuronal loss, amyloid senile plaques, loss of fiber tract integrity and tau lesions. In the context of AD, these changes have been described in the hippocampal formation and several parahippocampal structures. The list includes, but is not limited to, the hippocampus, the amygdala, the enthorinal cortex, the fornix, the stria terminalis and the parahippocampal gyrus. Table 2 lists several studies that have reported structural changes in these regions.
Using the template parcellation map [Oishi et al., 2010] , we considered 67,983 voxels that are part of the regions listed in Table 2 . These voxels represent 3.5% of the template and are potential candidates for association with AD. We use these voxels as a silver standard to evaluate the performance of the different normalization methods and RAVEL. For different values of k, we count the number of the top k voxels associated with AD that are in the silver standard, which are said to be enriched for the truth. The enrichment curves, depicted in Figure 5a (solid lines), show the number of enriched voxels for different values of k, for each normalization method. The dotted line at the bottom represents the number of voxels expected by chance only (y = 0.035k). To account for variability in the enrichment curves, we nonparametrically bootstrapped with replacement by subject to recalculate the top voxels associated with AD and recompute the curves. The shaded regions of Figure 5 represent bootstrapped 95% confidence bands. We observe that RAVEL discovers significantly more voxels that are truly associated with AD than the competing methods. The top voxels associated with RAVEL are also more stable than other methods, as measured by the width of the 95% confidence bands. Notably, RAVEL offers a substantial improvement with respect to intensity normalization with White Stripe alone.
Next, we obtained pseudo-ROC curves to measure the specificity and sensitivity of RAVEL for detecting Figure 5 . The top voxels associated with AD are enriched for the hippocampus and parahippocampal regions (a) For the top k voxels associated with AD (x-axis), the solid lines display the number of voxels out of the k voxels falling into five structures known to be associated with the progression of AD: the hippocampus, amygdala, enthorinal cortex, fornix and stria terminalis and parahippocampal gyrus. The dotted line represents the number of voxels expected by chance only. The shaded areas represent 95% confidence bands computed using 100 bootstrapped samples. (b) From the t-statistics measuring the association of the voxel intensities with AD, we present the pseudo-ROC curves for classifying a voxel as a member of the five regions described in (a). RAVEL shows significantly better sensitivity and specificity than the other methods for detecting hippocampus and parahippocampal changes associated with AD.
a true association between voxel intensities and AD. In Figure 5b , we present the pseudo-ROC curves for classifying voxels as associated with AD or not, using the differential analysis (voxel-wise) t-statistics as a measure of association. The voxels from the regions listed in Table 2 are used as a silver standard. As with the enrichment curves, we present bootstrapped 95% confidence bands. RAVEL outperforms histogram matching, White Stripe and raw image intensities for the full range of specificity.
In Supplementary Figure S2 , we show in template space the negative log p-value at each voxel for association between the intensities and AD status.
RAVEL-corrected intensities improve prediction of AD and MCI
We investigated the potential use of T1-w RAVEL-corrected intensities as biomarkers for disease identification and progression. We first compared the average hippocampal intensity between AD patients and healthy controls. We used the template parcellation map to identify the 9847 voxels labelled as hippocampus. Using the mean intensity of the hippocampus as a score, we classified each subject as either having AD or being healthy, thresholding the scores at different levels. The corresponding ROC curves are presented in Figure 6a . ([48.4, 57.3] ). This shows that RAVEL-corrected intensities are more representative of true biological variation than intensity-normalized intensities alone, indicating that the development of biomarkers using MRI studies in many neurological and psychiatric disorders could benefit from the RAVEL scan effect correction tool.
Discussion
In this work, we have presented the scan effect correction tool RAVEL, to correct for inter-scan unwanted variability in MRI studies that is present after intensity normalization. We have shown that RAVEL, applied after normalizing the intensities with White Stripe [Shinohara et al., 2014] , substantially improves the replicability of the regions of the brain found to be the most associated with AD. RAVEL, inspired by the batch effect correction tools SVA and RUV Storey [2007, 2008] , Gagnon-Bartsch and Speed [2012] , infers the unwanted variation in the images by using regions of the brain that are not associated with disease. After registering all images to a common template, we used voxels that were labelled as CSF for all images as control voxels. We used a linear regression model at each voxel to regress out the variation in the intensities explained by variation in the control CSF voxels intensities. We used an SVD to reduce the dimensionality of the control voxels, and selected the number of components to include in the regression models by maximizing the replication rate of biological findings between independent subsets of the data.
We have shown that while common intensity normalizations remove a large part of the unwanted site effects for T1-w imaging, significant unwanted variation remains uncorrected. We encapsulated this postnormalization residual variability using the term scan effect. We have shown that the scan effect correction tool RAVEL successfully improves the comparability of the images in a large subset of the ADNI database by removing this extra variability. We measured the performance of RAVEL and other methods by estimating the replicability of the top voxels associated with AD in independent subsets of the ADNI dataset.
To do so, we randomly divided the ADNI dataset into discovery and validation cohorts several times, and computed the top-replicated voxels for each random split. We have also shown that the top voxels associated with AD in our analysis and replicated in the discovery-validation division are more enriched for brain regions known to be associated with AD than those found using intensity-normalized data only. This shows that RAVEL is a potent method for improving the discovery of brain regions associated with disease. Finally, we have also shown that the RAVEL correction improves the prediction of AD and MCI compared to healthy controls, using the mean hippocampal intensity as a predictor. This suggests that RAVEL is a promising method that may facilitate the development of biomarkers using MRI intensities. Furthermore, with the recent emphasis on multivariate pattern analysis for biomarker development [Davatzikos et al., 2005 , De Martino et al., 2008 , Vemuri et al., 2008 , Craddock et al., 2009 , Davatzikos et al., 2011 , Gaonkar and Davatzikos, 2013 , RAVEL promises to produce more generalizable biomarkers that are less susceptible to biases associated with scanner and site imbalances.
The idea of using a control region of the brain which is not associated with disease is not new. In [Pujol et al., 1992 , Bakshi et al., 2002 , Tjoa et al., 2005 , Brass et al., 2006 , Neema et al., 2009 , the regions of interest were divided by the mean signal intensity of a CSF region to correct for potential inter-subject variation. Shinohara et al. [2014] used a NAWM stripe to estimate a scaling and shifting parameter in their z-score normalization method. In Mejia et al. [2015] , in the context of estimating quantitative T 1 maps (qT 1 ) from conventional MRI, the authors proposed an adaptation of the z-score normalization method by using a combination of NAWM and cerebellar gray matter (CBGM), where the NAWM was used for the scaling parameter and the CBGM was used for the shifting parameter. In [Ghassemi et al., 2015] , the authors used the median GM intensity for the shifting parameter, and the difference between the median intraconal orbital fat intensity and the median GM intensity for the scaling parameter. In [Sweeney et al., 2013] , the authors use the whole brain to estimate the two parameters. We note that the different versions of the z-score transformation used in [Shinohara et al., 2014 , Sweeney et al., 2013 , Mejia et al., 2015 , Ghassemi et al., 2015 only leave room for the choice of two control regions at maximum, corresponding to the mean and scale parameters. While this improves comparability between subjects in comparison to the unnormalized intensities, as shown in Figure 4b , we have shown that RAVEL improves dramatically upon a z-score transformation only.
There are several limitations to our method. If control regions are misspecified, i.e. the region does not carry any information about the technical variability across subjects, or worse yet, if the control regions are inadvertently associated with the outcome of interest, the RAVEL correction may remove biological signals of interest. In both cases, however, cross-validation using the concordance curves from the discoveryvalidation scheme introduced in Section 2.7, allows the user to estimate directly the performance of RAVEL on their dataset.
Another limitation is the use of nonlinear registration to align voxels across subjects. The registration step is necessary to apply the voxel-wise linear models from Equation 1. Because patients with AD and MCI have different volumes of WM, GM and CSF in comparison with healthy controls, misregistration error might be associated with the outcome of interest. However, this is a problem inherent to any cross-subject voxel analysis, and remains an active subject of research in image analysis. While voxels that are associated with disease can be a consequence of differential misregistration, this does not change the results of the present work, as misregistered voxels should be detected by intensity normalization method, after scan effect correction. It may also be possible to approximate RAVEL corrections using mean values in reference regions; indeed, in the ADNI the mean T1-w intensity in CSF after White Stripe correction was highly correlated with the first RAVEL factor. Thus, in the case of the well-controlled ADNI protocol, adjusting by regression on the mean in CSF would yield similar results. In cases where there is more heterogeneity in acquisitions, and in imaging modalities that are more difficult to calibrate, additional RAVEL factors are likely and using the mean in the reference region may not perform well.
A first extension of the presented methodology is to precede the RAVEL correction tool by a variant of the White Stripe intensity normalization method. For instance, as used in [Sweeney et al., 2013] , a wholebrain z-transformation might be used instead, where the mean and scaling parameters are estimating using all brain intensities. Subsequently, the RAVEL correction model can be applied using additional control regions, and mask erosion could be performed to improve the homogeneity of the selected control regions.
Although we have shown the performance of RAVEL in the context of T1-w MRI of the brain, RAVEL is a promising scan effect correction tool for many imaging modalities, such as quantitative images, maps derived from diffusion tensor imaging (DTI), functional imaging and many other modalities. Furthermore, the choice of the control regions, left to the user, makes the method applicable to virtually any disease and pathology. The RAVEL software can be found at https://github.com/Jfortin1/RAVEL. Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60mil-lion, 5-year public private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California San Francisco. ADNI is the result of the efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. To date these three protocols have recruited over 1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively normal older individuals, people with early or late MCI, and people with early AD. The follow-up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see www.adni-info.org. Figure S2 . Voxel-level p-value maps from AD vs. healthy patient differential analysis At each voxel, we computed a t-statistic for testing a difference in intensities between AD and healthy patients. For each normalization method, we report the negative log p-values from the t-test. We include at the top of the figure the template for anatomical reference.
